List of Intuniv drug patents

Intuniv is owned by Takeda Pharms Usa.

Intuniv contains Guanfacine Hydrochloride.

Intuniv has a total of 2 drug patents out of which 2 drug patents have expired.

Expired drug patents of Intuniv are:

  • US6811794
  • US6811794*PED

Intuniv was authorised for market use on 02 September, 2009.

Intuniv is available in tablet, extended release;oral dosage forms.

Intuniv can be used as treatment of attention-deficit hyperactivity disorder.

The generics of Intuniv are possible to be released after 04 January, 2023.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6811794 TAKEDA PHARMS USA Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
Jul, 2022

(7 months ago)

US6811794

(Pediatric)

TAKEDA PHARMS USA Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
Jan, 2023

(a month ago)

Drugs and Companies using GUANFACINE HYDROCHLORIDE ingredient

Market Authorisation Date: 02 September, 2009

Treatment: Treatment of attention-deficit hyperactivity disorder

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of INTUNIV before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic